Annexon biosciences reports promising interim phase 2 data showing improvement in clinical measures with anx005 in huntington's disease following six-month treatment

Anx005 has been generally well-tolerated and has shown full target engagement of c1q in the csf

ANNX Ratings Summary

ANNX Quant Ranking